Pharmacological ascorbate has been proposed as a potential anti-cancer agent when combined with radiation and chemotherapy. The anti-cancer effects of ascorbate are hypothesized to involve the autoxidation of ascorbate leading to increased steady-state levels of H2O2; however, the mechanism(s) for cancer cell-selective toxicity remain unknown. The current study shows that alterations in cancer cell mitochondrial oxidative metabolism resulting in increased levels of O2⋅- and H2O2 are capable of disrupting intracellular iron metabolism, thereby selectively sensitizing non-small-cell lung cancer (NSCLC) and glioblastoma (GBM) cells to ascorbate through pro-oxidant chemistry involving redox-active labile iron and H2O2. In addition, preclinical studies and clinical trials demonstrate the feasibility, selective toxicity, tolerability, and potential efficacy of pharmacological ascorbate in GBM and NSCLC therapy.
Pubmed ID: 28366679 RIS Download
Mesh terms: Animals | Antineoplastic Combined Chemotherapy Protocols | Ascorbic Acid | Brain Neoplasms | Carcinoma, Non-Small-Cell Lung | Cell Line, Tumor | Chemoradiotherapy | Female | Glioblastoma | Humans | Hydrogen Peroxide | Iron | Lung Neoplasms | Male | Mice, Nude | Oxygen | Radiation-Sensitizing Agents | Xenograft Model Antitumor Assays
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.